eligibility_summary
Eligibility: Patients ≥18 with LDGCB, planned for anti‑CD19 CAR‑T, with informed consent (CART-BANK written, CARTROG oral) and social insurance. Healthy volunteers: oral consent, age 18–70, no cancer history, no chronic disease or daily meds, no surgery in past 6 months. Exclude: not meeting criteria, pregnant/breastfeeding, unable to adhere to visits, or unable to consent (e.g., under guardianship/curatorship/safeguard of justice).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial goal: determine if early trogocytosis on immune effector cells predicts outcomes after anti‑CD19 CAR‑T in R/R DLBCL. Interventions: serial blood draws with flow cytometry (patients at D0, D3, D7, D10, D30, single sample in healthy donors) to quantify a “trogocytosis signature.” Drug/therapy context: anti‑CD19 CAR‑T cells (autologous, genetically engineered cellular immunotherapy) that recognize CD19 on B cells to trigger T‑cell cytotoxicity. Mechanisms assessed: trogocytosis—immune cells acquiring tumor membrane fragments/markers, potentially altering effector function and persistence. Cells/pathways targeted: CD19+ B‑cell lymphoma, effector cells including CAR‑T, conventional T lymphocytes, and NK cells, surface phenotypic markers indicative of trogocytosis. Outcome focus: predict 6‑month response and immunologic/hematologic toxicities.